INS and metabolic dysfunction-associated steatohepatitis: Clinical trials with UDCA caused a significant reduction in fasting plasma glucose and insulin concentrations thereby improving glucose homeostasis in patients with T2DM and MASLD/MASH, however, UDCA failed to improve liver histology of MASH patients [138–140].